Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. (the "Company") today announced that its TROP2-directed antibody-drug conjugate (ADC) sacituzumab tirumotecan (sac-TMT) (佳泰莱 ®) in combination with ...

Dr. Suresh Ramalingam discusses how Tagrisso has ushered in a new era of care for patients with advanced EGFR+ non-small cell ...

The Scorpion Therapeutics spinoff sold rights for two EGFR inhibitors to Pierre Fabre Laboratories and is hoping to become a clinical-stage firm by 2026.